Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia.
Hypercholesterolemia causes endothelial dysfunction , an early feature of atherosclerosis , leading to increased production of adhesion molecules and cytokines . The aim of this study was to investigate the effects of three months of treatment with low dose atorvastatin on serum levels of adhesion molecules , interleukin-6 ( IL-6 ) and highly sensitive C-reactive protein ( hs-CRP ) in patients with non-familial hypercholesterolemia . Fifty-five patients with non-familial hypercholesterolemia were r and omized to treatment with atorvastatin 10 mg/day or placebo for 3 months . Soluble intercellular adhesion molecules-1 ( ICAM-1 ) , vascular cell adhesion molecule-1 ( VCAM-1 ) , E-selectin , IL-6 and hs-CRP levels were measured to assess the inflammatory activity of the endothelium . There was a significant reduction in ICAM-1 at 2 weeks ( p<0.0001 ) with further reduction at 3 months ( p<0.0001 ) . At 3 months , there were significant reductions in VCAM-1 ( p<0.02 ) , IL-6 ( p<0.0001 ) and hs-CRP ( p<0.01 ) , but an increase in E-selectin levels ( p<0.002 ) . Treatment with statin was an independent determinant of change in ICAM-1 ( p<0.05 ) and IL-6 levels ( p<0.05 ) after correcting for anthropometric indices , blood pressure and lipid profile . Low-dose atorvastatin treatment leads to reduction in proinflammatory markers of endothelial function , suggesting an attenuation of endothelial activation and improvement in endothelial function , independent of lipid lowering . This may lead to a reduction in the progression of atherosclerosis
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .